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with parents
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Abstract
Background: Infantile spasms (IS; West syndrome) is a severe form of encephalopathy that typically affects infants
younger than 2 years old. Pediatricians, pediatric neurologists, and other pediatric health care providers are all
potentially key early contacts for families who have an infant with IS. The objective of this article is to assist
pediatric health care providers in the detection of the disease and in the counseling and guidance of families who
have an infant with IS.
Methods: Treatment guidelines, consensus reports, and original research studies are reviewed to provide an update
regarding the diagnosis and treatment of infants with IS. Web sites were searched for educational and supportive
resource content relevant to providers and families of patients with IS.
Results: Early detection of IS and pediatrician referral to a pediatric neurologist for further evaluation and initiation
of treatment may improve prognosis. Family education and the establishment of a multidisciplinary continuum of
care are important components of care for the majority of patients with IS. The focus of the continuum of care
varies across diagnosis, initiation of treatment, and short- and long-term needs. Several on-line educational and
supportive resources for families and caregivers of patients with IS were identified.
Conclusions: Given the possibility of poor developmental outcomes in IS, including the emergence of other
seizure disorders and cognitive and developmental problems, early recognition, referral, and treatment of IS are
important for optimal patient outcomes. Dissemination of and access to educational and supportive resources for
families and caregivers across the lifespan of the child with IS is an urgent need. Pediatric health care providers are
well positioned to address these needs.
Keywords: West syndrome, Encephalopathic epilepsy, ACTH, Vigabatrin, Infantile spasms, Treatment, Continuum of
care, Community resources, Seizures, Infants
Background
Infantile spasms (IS; West syndrome) is a severe form of
epilepsy of early infancy [1]. Although IS was first de-
scribed over 160 years ago [1], its diagnosis, evaluation,
and management continue to pose many challenges to
health care professionals and affected families. Educating
pediatricians and general pediatric health care providers
about IS may be especially important as a recent IS
working group (ISWG) of pediatric neurologists re-
viewed the literature and determined that early recogni-
tion of IS and prompt treatment are mandatory and may
improve developmental and cognitive outcomes in some
patients [2]. IS presents with myoclonic-tonic seizures
(spasms) that may be characterized by flexor, extensor,
or mixed movements, a distinct electroencephalogram
(EEG) pattern of hypsarrhythmia, and psychomotor
delay/arrest [3]. The incidence of IS ranges from 2 to
3.5/10,000 live births, with onset during the first year
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of life in 90% of those affected. This translates to ap-
proximately 2,000 to 2,500 new cases per year in the
United States. The peak age of onset is between 3 and
7 months; onset after 18 months is rare, though onset
up to 4 years of age has been reported [4]. Spasms
usually cease by 5 years of age, but other seizure types
are reported in as many as 60% of children with IS
even after cessation of spasms [5]. IS occurs in chil-
dren from all ethnic groups, and boys are affected
slightly more often than girls (ratio of 60:40) [6-8].
The etiologic classification of IS includes the categor-
ies of cryptogenic and symptomatic. The cryptogenic
form of IS occurs in 10% to 40% of IS patients. In infants
with cryptogenic IS, no underlying cause is identified
and the children have normal development prior to the
onset of IS [9]. Outcomes are usually more favorable
among children with cryptogenic IS than symptomatic
IS, and early effective treatment in cryptogenic cases is
associated with improved prognosis [10-16].
Within symptomatic IS, a defined underlying cause is
present, usually with developmental delay at onset of
spasms. The percentage of IS cases classified as symp-
tomatic has increased over time due to improved diag-
nostic techniques, such as metabolic and genetic testing
and neuroimaging. It is estimated that approximately
60% (in living infants) to 90% (in autopsy neuropatho-
logical analysis) of children with IS have an associated
underlying disorder that is evident [6,17]. Causes of IS
may be prenatal, perinatal, or postnatal. Approximately
50% of cases have a prenatal cause, including central ner-
vous system malformations, intrauterine insults, neuro-
cutaneous syndromes such as tuberous sclerosis complex
(TSC), metabolic disorders, or genetic syndromes such
as Down syndrome. Identification of genetic associations
of IS, a rapidly developing area, suggests IS is a genetic-
ally heterogeneous condition involving abnormalities in
key developmental pathways in the ventral forebrain and
synaptic functional pathways [18]. Perinatal causes in-
clude neonatal (hypoxic-ischemic) encephalopathy, and
postnatal causes include trauma, infection, and, rarely,
tumors. TSC is an important cause of symptomatic IS
[19], and the development of IS in children with TSC is
closely associated with the development of autistic
spectrum disorder in later years [20,21]. The appearance
of IS in TSC may be atypical with either the appearance
of spasms but no hypsarrhythmia, or the appearance of
an abnormal EEG but no spasms. To optimize treatment
outcomes, it is recommended that treatment of IS in
children with TSC not be delayed while waiting for either
hypsarrhythmia to appear or for spasms to begin [22,23].
Methods
PubMed was searched for IS treatment guidelines, con-
sensus reports, and original research studies. Relevant
studies were reviewed to provide an update regarding
the diagnosis and treatment of infants with IS. Web sites
were searched for educational and supportive resource
content relevant to providers and families of patients
with IS.
Results
Pathophysiology
Little is known about the pathophysiology of IS. The
causes of IS appear to be extremely variable [24], and a
common mechanism by which all of the different etiolo-
gies of IS might converge to lead to spasms has been
proposed [25]. Current IS animal models either focus on
a specific cause of IS, such as the loss of interneurons (i.e.,
the ARX mouse model), or propose a final common
pathway underlying all causes of IS [26]. The stress/
corticotropin-releasing hormone (CRH) hypothesis pro-
poses that the common mechanism in all the etiologies
of IS causes an increase in the release of stress-activated
mediators in the brain, especially the neuropeptide CRH
in the limbic and brain stem regions in children with IS
[27]. Adrenocorticotropic hormone (ACTH) suppresses
the synthesis of CRH, which might explain the treatment
efficacy of this stress hormone in IS [27,28]. Other ani-
mal models of IS focus on the proposed common path-
way of loss of inhibition. The suggested mechanism for
the effectiveness of vigabatrin within IS is through its
effects as an irreversible inhibitor of γ-aminobutyric acid
transaminase (GABA-T) [29].
Diagnosis
In the great majority of cases, parental observation of
spasms initiates the clinical evaluation of IS [30-32].
Parents typically bring the child to the pediatrician for
episodes that look like colic or may be mistaken for gas-
troesophageal reflux. Parental/caregiver videos of infant
spasms may assist with the clinical evaluation. Consult-
ation with a pediatric neurologist is warranted as early
as possible if the events on video are suspicious. The po-
tential benefits of early diagnosis and treatment cannot
be overemphasized as improved neurodevelopment may
result [33].
Spasms vary greatly depending upon the muscle
groups involved, the intensity of the contraction, and
position of the infant during the attack, that is, whether
supine or sitting. Spasms may be subtle, brief, and sud-
den, the most subtle being a head nod or tonic eye roll-
ing, which may be easily missed; they also show great
variability in frequency [32,34]. Typically the spasms in-
volve brief symmetrical contractions of musculature of
the neck, trunk and extremities lasting up to 5 seconds
and occurring in clusters [7,9]. In most cases there is an
initial phasic component lasting less than 1 to 2 seconds,
followed by a less intense but generally more sustained
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tonic contraction, which could last up to about 10 sec-
onds. However, in some children this tonic phase may
be absent and only the initial phasic component is seen.
The number of spasms can vary from a few to more
than a hundred per cluster; the duration of a cluster may
vary from less than a minute to more than 10 minutes.
Among many available web-based videos of IS spasms,
the Tuberous Sclerosis Alliance provides an IS informa-
tional video depicting spasms, currently found on You-
Tube at http://www.youtube.com/watch?v=35wRjuvg9MI
(see Table 1).
In addition to clinical spasms, the defining features of
IS include hypsarrhythmia (a specific EEG pattern) and
developmental regression. Even a brief EEG recording
may confirm the diagnosis, but if IS is suspected, a pro-
longed awake and asleep video-EEG study is recom-
mended [34]. Interictal (between spasms) EEGs of IS are
characterized by hypsarrhythmia as well as chaotic, non-
rhythmic, asynchronous, disorganized, high-voltage spike
activity and slow-wave activity [9,34]. The hypsarrhyth-
mic pattern is most frequent during stages 2/3 of non-
rapid eye movement (non-REM) sleep, followed by wak-
ing and arousal, and it does not occur or is greatly
reduced during REM sleep [35,36].
The recommended approach to EEG evaluation, dur-
ing the diagnostic evaluation and during follow-up to
determine treatment effectiveness, is an overnight in-
patient 24-hour video EEG to capture both hypsarrhyth-
mia and spasms. It will allow the exclusion of other
movements that may mimic IS and allow the investiga-
tion of other seizure types that may be occurring. If hyp-
sarrhythmia or spasms do not occur, and the events
continue at home, the EEG should be repeated in 1 week
or as clinically indicated. If developmental regression is
present, the EEG should be repeated earlier than 1 week.
If an inpatient video EEG is not available, a prolonged
4-hour to 8-hour EEG video during a waking and sleep
period may be completed as an outpatient; it is particu-
larly important to capture non-REM sleep.
Once spasms and hypsarrhythmic EEG have been
documented, determining the cause of IS becomes the
focus of the clinical evaluation [30-32]. The goal is to
Table 1 Organizations providing IS information and family resources
Organization Website Key resources
American Epilepsy Societya http://www.aesnet.org • Provides links to drug assistance programs,
treatment guidelines, research publications
Epilepsy Foundation http://www.epilepsyfoundation.org • IS fact sheets and awareness
Epilepsy Information
Service of Wake Forest
Health Sciencesa
http://www.wakehealth.edu/Neurosciences/
Comprehensive-Epilepsy-Center/
Epilepsy-Resources.htm
• Epilepsy information toll free hotline,
vigabatrin access assistance, support groups
Epilepsy Therapy Project http://www.epilepsy.com • IS fact sheets
HopefulCircle.org http://www.hopefulcircle.org • A rare diseases online community where
patients, caregivers, healthcare professionals,
and organizations can come for support
and resources
Infantile Spasms
Awareness
http://infantilespasmsinfo.org • IS education and information for
pediatricians and parents
Lundbeck, Inc http://www.lundbeckshare.com • Comprehensive vigabatrin resource for
healthcare providers and patients/families;
distribution access to vigabatrin
National Institute of
Neurological Disorders
and Stroke (NINDS)
http://www.infantilespasms.org • Infantile spasms information page with
overview on IS
National Organization
for Rare Disorders (NORD)
http://www.rarediseases.org • Patient Assistance Programs
• Online support community,
ACTH access assistance
Questcor Pharmaceuticals http://www.questcor.com • The Acthar Support & Access Program
(ASAP) for prescriptions and reimbursement
support related to ACTH treatment
Tuberous Sclerosis
Alliancea
http://www.tsalliance.org • Fact sheets on IS in children with TSC
• IS video (http://www.youtube.com/
watch?v=35wRjuvg9MI)
• Online discussion groups
• Links to www.seizuretracker.com
aOrganizations that provide resources specifically for health care providers.
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identify potentially treatable disorders while remember-
ing that early treatment is thought to have an improved
developmental outcome in many infants. There are sev-
eral etiological diagnoses that may respond to specific
therapies and lead to resolution of IS (see Table 2). Ap-
proximately 30% of children with IS will have no identi-
fiable cause following completion of the history,
physical, neurological and ophthalmological (possibly re-
vealing infections, phacomas, and malformations) exam-
ination, EEG, and magnetic resonance imaging. Of these
remaining 30% of children, a metabolic or genetic eti-
ology will likely be established for fewer than 50%. For
these 30% of infants with IS, pyridoxine dosed at 100 mg
IV may be administered to screen for pyridoxine-
dependent seizures [37]. Pyridoxine should be given dur-
ing an EEG or an EEG should be repeated following
administration of pyridoxine. Additional metabolic eval-
uation, depending on the individual circumstances, may
include urine for organic acids, serum for amino acids,
biotinidase determination, lumbar puncture to include
neurotransmitters, lactic acid, amino acids, folate meta-
bolites, cerebrospinal fluid glucose, glycine, cells, pro-
teins, IgG index, viral antibody index, and chromosomal
studies. Immunoglobulin production can be active for a
long time, even years after a primary infection, and
infections may represent 10% of IS etiology [38]. A small
number of children with IS due to malformations of cor-
tical development, typically involving the posterior quad-
rant of the brain, are a special subset who may benefit
from epilepsy surgery. The remaining children without
an identifiable cause will be labelled as cryptogenic.
Treatment
Recently, an IS consensus group reviewed the most re-
cent practice guidelines from the American Academy of
Neurology and the Child Neurology Society for the med-
ical treatment of IS [37], and outlined goals for improv-
ing outcomes in IS [2]. The IS consensus group goals for
improving IS outcomes include early detection and diag-
nosis of IS, short-duration treatment with first-line ther-
apy (agreed upon as either ACTH or vigabatrin), timely
EEG evaluation of treatment effectiveness, and, if indi-
cated, prompt treatment modification [2]. Early detec-
tion of IS is critical. Studies suggest the need for early
detection and prompt effective treatment to improve
neurodevelopmental outcomes, particularly in crypto-
genic cases [10-16]. Evaluation of treatment effectiveness
for IS includes cessation of spasms and normalization of
the EEG in cryptogenic cases and a resolution of hypsar-
rhythmia on the EEG in symptomatic cases [34,37,39].
Successful cessation of spasms and resolution of hypsar-
rhythmia is considered an “all-or-none” response rather
than a graded response to treatment [32,39].
The most recent practice guidelines from the Ameri-
can Academy of Neurology and the Child Neurology So-
ciety for the medical treatment of IS, which reviewed the
available evidence as of 2004, state that ACTH is prob-
ably effective and vigabatrin is possibly effective in the
cessation of spasms and abolition of hypsarrhythmia
[37]. The practice guidelines also state that vigabatrin is
possibly effective for children with TSC and IS. Vigaba-
trin was approved for treatment of IS in the United
States in August 2009, and an ACTH gel was approved
Table 2 Metabolic and other etiological diagnoses that respond to specific therapy
Diagnosis Specific therapy
Pyridoxine-dependent seizures Pyridoxine
Phenylketonuria Diet
Maple syrup urine disease Diet
Biotinidase deficiency Biotin
Menkes disease Copper histidinate
Hyperammonemia disorders Possibly diet, depending on
which disorder
Nonketotic hyperglycinuria Benzoate
Tumor Surgery
Arterial-venous malformation Surgery
Sturge-Weber syndrome Surgery if medications fail
Tuberous sclerosis complex Vigabatrin, ACTH (if vigabatrin fails), and
possibly surgery if medications fail
Cortical dysplasias: focal cortical dysplasias,
hemimegalencephaly
Possible cortical resection if
medications fail
Malformations of cortical development Epilepsy surgery
Courtesy of Dr Shields.
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for treatment of IS in the United States in October 2010.
When the practice guidelines were published, there was
insufficient evidence to recommend oral corticosteroids
or valproic acid as first-line treatments in IS; however,
since then, high-dose oral prednisolone has been
reported to possibly be effective [12,40].
Children with IS who do not respond to first-line
treatments may be considered for epilepsy surgery (only
those children with surgical lesions are candidates) or
the ketogenic diet, though no controlled trials are avail-
able for the efficacy of the ketogenic diet in IS. There
currently is insufficient evidence to recommend proto-
cols using new or emerging therapies for IS [37]. The
evolution over time of spasms to other forms of epilepsy
may then require the use of conventional antiepileptic
drugs; however, evidence does not support the clinical
efficacy of benzodiazepines, phenobarbital, or most other
conventional antiepileptic drugs as effective treatments
for IS [37].
ACTH
There was consensus among the ISWG that use of
ACTH is effective as first-line therapy for IS. Within the
United States (US), natural ACTH is used, whereas out-
side the US tetracosactide, a synthetic ACTH com-
pound, is frequently used. There was insufficient
evidence to precisely define the optimum ACTH dose
and duration of treatment for IS, although short dur-
ation was preferable (i.e., approximately 2 weeks fol-
lowed by taper) [2]. ACTH is given using intramuscular
injection. Effective short-duration treatment may avoid
major side effects associated with IS treatment [41]. The
most frequent adverse effects associated with short-
duration ACTH treatment are irritability, increased
appetite leading to weight gain [39], and Cushingoid fea-
tures. Less frequently seen, but more severe, are hypo-
kalemia and hypertension. Possible serious adverse
events include fulminant infections secondary to im-
munosuppression, glucosuria, and metabolic abnormal-
ities [42]. ACTH followed by long-term treatment with
high-dose glucocorticoids in IS patients has been asso-
ciated with reduced bone mineral density later in life,
and such patients may benefit from a calcium-rich diet,
monitored vitamin D level, and weight-bearing physical
exercise [43]. In all cases, safety measures should be in
place (see Table 3). Due to possible immunosuppression,
any fever (temperature greater than 101°F rectally) or
intercurrent illness should prompt urgent and immediate
evaluation by medical personnel. Additionally, live vacci-
nations should be avoided for 6 months following cessa-
tion of therapy due to possible immunosuppression.
Similar to high doses of prednisolone, ACTH may sup-
press the hypothalamic-pituitary-adrenal (HPA) axis
resulting in adrenal hypofunction and low cortisol levels.
As a result, HPA function should be monitored and
hydrocortisone may be needed in patients experiencing
stressful situations.
Vigabatrin potential adverse events
There was consensus among the ISWG for the use of
vigabatrin as effective first-line therapy for IS, particu-
larly in patients with IS and TSC [2]. The consensus sta-
ted that the vigabatrin dose should begin at 50 mg/kg/
day and be escalated up to 100-150 mg/kg/day in those
patients requiring escalation. Efficacy should be assessed
within 2 weeks following dose titration. The ISWG con-
sensus report and a review of limited data available from
well-controlled clinical trials both state that infants who
respond well to therapy with vigabatrin may be contin-
ued on the drug for up to 6-9 months with continued
ophthalmic evaluation and periodic reevaluation of risk
and benefit [2,44]. Vigabatrin is taken by mouth. Among
possible adverse events associated with vigabatrin treat-
ment (50-150 mg/kg/day), the most significant is concen-
tric peripheral visual field defects (i.e., pVFD, retinopathy
involving loss of peripheral vision in both eyes) [37].
These visual field defects, once present, are permanent
and persist even when vigabatrin is discontinued. A re-
cent study of children with IS treated with vigabatrin in
early infancy found that 1 in 16 (6%) showed vigabatrin-
Table 3 Suggested safety measures during IS treatment with ACTH and vigabatrin
ACTH Vigabatrin
Baseline hematology X X
Baseline serum chemistries (i.e., SMA 20) X X
Day 3 serum chemistries (especially potassium) X
Twice weekly:
Blood pressure X
Stool guaiac X
Urine glucose X
Periodic ophthalmic evaluations and visual history X
Periodic clinical exam and review of potential side effects X X
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attributed visual field loss when evaluated at age 6 to
12 years [45]. The study [45] needs to be replicated in a
larger number of children treated in infancy and old
enough to cooperate with detailed testing to confirm
these preliminary data. The duration of therapy, cumula-
tive dose, and daily dose have been implicated as risk fac-
tors for visual field changes with vigabatrin use [46].
Accurate assessment of visual field changes in infants is
challenging. A recent expert consensus protocol for vis-
ual evaluation for infants on vigabatrin presents recom-
mendations for visual function evaluations by the child’s
developmental age and/or ability, to be performed by
neurologists and ophthalmologists [46]. A history of the
patient’s visually-oriented behavior (e.g., bumping into
objects or ignoring objects in the environment) should
be obtained from parents or caregivers [46,47]. Because
infants and young children with IS are unable to perform
perimetry, confrontation testing in which small toys of
interest are held in the peripheral field to see if any eye
movement occurs is recommended as a qualitative as-
sessment to identify patients who may have pVFD and
may require additional testing [46,47]. A full-field elec-
troretinogram (ERG) is recommended as the primary
screening modality for infants and children younger than
2 years, however, the risk of required sedation needs to
be considered for each patient [46]. A visual history
should be performed at every clinic visit in children trea-
ted with vigabatrin. In the US, vigabatrin is available only
under a special restricted distribution program (i.e., the
Support, Help and Resources for Epilepsy [SHARE] pro-
gram; www.lundbeckshare.com). Children on vigabatrin
are required to have periodic ophthalmic evaluations be-
ginning with a baseline evaluation at initiation of therapy
(no later than 4 weeks after starting treatment) and at
least every 3 months while on therapy, as well as 3 to
6 months after cessation of treatment (see Table 3).
Other adverse side effects with vigabatrin therapy include
sedation, irritability, insomnia, and hypotonia [48-51].
Discussion
Establishing a continuum of care
Diagnosis
Education about IS, treatment options, and a continuum
of care is an ongoing process begun at the first contact
with the child and family during the clinical evaluation
and diagnosis, and continued as the treatment plan is
developed. The methods for establishing a continuum of
care with close follow-up will vary depending on medical
center and physician preferences, and comorbid con-
ditions of the infant with IS. In addition to general in-
formation about IS etiology, prognosis, and any issues
associated with comorbid disorders, parents/caregivers
should be educated about treatment options in order to
make informed decisions. Detailed information regarding
administration of medication and possible side effects,
as well as who to contact if there are problems or ques-
tions, and when to make contact, should be discussed.
Parents/caregivers would benefit from information re-
garding resources that assist with access to treatment
(see Table 1). The Acthar Support and Access Program
(A.S.A.P.) and the National Organization for Rare Dis-
orders (NORD) may be especially helpful for access to
Acthar Gel. The SHARE program, developed to assist
with access to vigabatrin in the US, provides informa-
tion about vigabatrin and provides prescription support.
In the US, vigabatrin is currently only available through
the SHARE Program due to the potential adverse risk
of permanent vision loss.
Initiation of treatment
Parental/caregiver education and training is required to
prepare for administering treatment at home [52]. Before
initiating treatment at home, parents/caregivers should
have all relevant emergency contact phone numbers and
the plan of contact should be determined. For example,
it should be clarified whether the treating pediatric neur-
ologist is the direct contact for parents/caregivers or the
general pediatrician is the first contact and will consult
with the pediatric neurologist as needed. The availability
of a home health nurse in the early transition from the
hospital to home care can be very helpful for parents/
caregivers to ensure adequate training in treatment ad-
ministration, to relieve stress, and to provide support.
Short-term needs
Following the transition from treatment in the hospital
to home care, the health care provider network for the
child with IS and the overall medical and psychosocial
treatment plan should be discussed. All health care pro-
viders who will be involved in the child’s care should be
identified and the specific treatment plan should be
determined. Discussion of potentially useful strategies to
manage side effects such as irritability will help alleviate
caregiver stress and may improve treatment adherence.
Especially important is the identification of specific ad-
verse effects that caregivers should look for that indicate
the need to immediately contact the treating physician.
Once the treatment plan has been established, discus-
sion of multidisciplinary resources for children with IS
and their families is needed due to potentially lifelong
needs related to medical care and poor developmental
outcomes. Parents and caregivers need to be aware of
available coping resources to assist with the emotional
and psychosocial impact of the IS diagnosis (see below).
This is particularly important as parent/caregiver dis-
tress may interfere with the ability to comply with pro-
viding medical care to the child at home.
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Long-term needs
Given the possibility of poor developmental outcomes in
IS, including the emergence of other seizure disorders
and cognitive and developmental problems [7,53], the
establishment of a long-term multidisciplinary contin-
uum of care for children with IS is important. With the
possible exception of children diagnosed with crypto-
genic IS who show cessation of spasms and hypsarrhyth-
mia in response to treatment, access to and evaluation
by a variety of professionals, such as child neurologists,
developmental pediatricians, child psychiatrists, pediatric
nurse practitioners, nurses, specialists in rehabilitation
services (physical, occupational, and speech therapy), vo-
cational rehabilitation counselors, neuropsychologists,
social workers, pharmacists, and others is needed. Long-
term neuropsychological and psychological evaluation
may be especially critical for assessing developing cogni-
tive and psychosocial abilities important for the patient’s
function and to identify areas in need of intervention or
external support. The comprehensive ‘village’ of resources
should include the integration of resources from health
care practitioners, social service professionals, and com-
munity agencies [54].
Children with IS often require an evaluation for early
intervention programs for developmental impairment.
Because available resources vary by community and
by state, parents/caregivers should ask the treating
physician about local services. Additionally, parents/
caregivers can search for services using the Internet, ask
about listings of social services at their local library, and
determine whether their county of residence publishes
information about social services and resources relevant
for IS and comorbid disorders. Parents/caregivers are
encouraged to create a support network and engage
family and friends in the search for information and ser-
vices. Persistence is important; if initial contacts do not
lead to desired services, parents/caregivers should seek
assistance from alternative service organizations. The
optimal management of IS is complex, and care across
the lifespan may be complicated by ongoing seizures, in-
tellectual disability and learning disorders, or behavioral
and/or psychological issues. Adults who have a history
of IS may require discussion of future guardian issues,
group home applications, and respite care options [54].
Resources for families and health care providers
IS overview and support resources
Table 1 lists organizations that provide information
about IS and provide family and health care provider
resources. Given the relative rarity of IS, these online
resources allow widespread access to IS medical infor-
mation by physicians and families and provide web-
based support forums for families. Available resources
include fact sheets about IS, including information about
the disorder, treatment options and outcomes, and on-
line communities; forums for parents/caregivers of chil-
dren with IS to communicate with one another and
provide support. Family caregivers should be cautioned
that medical information obtained within an online
community should be discussed with the treating phys-
ician to verify its accuracy.
Treatment and health care provider resources
Assistance programs for children with IS help uninsured
and under-insured families gain access to medications
and financial support (premium/co-payment assistance
program) by working with pharmaceutical companies
and insurance plans (see Table 1). Assistance with phys-
ician referrals is also available. For example, the Tuber-
ous Sclerosis Alliance has created a provider list for TSC
clinics. Health care provider resources are also available,
including links to treatment guidelines, research publica-
tions, and online community discussion groups for med-
ical professionals.
Conclusions
IS imposes a significant ongoing challenge to the child’s
family and caregivers, as well as to health care profes-
sionals. Early detection and referral to a pediatric neurolo-
gist for clinical evaluation and prompt effective treatment
is strongly recommended as it may improve prognosis.
To best navigate the medical environment and optimize
clinical care, the child’s family and caregivers need access
to up-to-date information about IS, effective treatments,
and establishment of a multidisciplinary continuum of
care, which includes access to resources for psychosocial
support. Further dissemination of and access to educa-
tional and supportive resources for families and care-
givers across the lifespan of the child with IS is an urgent
need.
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